CLL (chronic lymphocytic leukemia)
Clinical trials for CLL (chronic lymphocytic leukemia) explained in plain language.
Never miss a new study
Get alerted when new CLL (chronic lymphocytic leukemia) trials appear
Sign up with your email to follow new studies for CLL (chronic lymphocytic leukemia), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could bone marrow from deceased donors cure blood cancers?
Cure Not yet recruitingThis study tests whether bone marrow from deceased donors can be used to treat people with blood cancers like leukemia and lymphoma. Participants receive a transplant of cryopreserved marrow from a deceased donor or standard cells from a living donor. The goal is to see if the de…
Matched conditions: CLL (CHRONIC LYMPHOCYTIC LEUKEMIA)
Sponsor: Ossium Health, Inc. • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Can a bispecific antibody wipe out residual leukemia cells in High-Risk CLL?
Disease control Not yet recruitingResearchers are testing whether adding epcoritamab can help high-risk chronic lymphocytic leukemia (CLL) patients who are already taking a BTK inhibitor clear remaining cancer cells. The trial enrolls 24 adults with CLL and specific risk factors such as a 17p deletion, TP53 mutat…
Matched conditions: CLL (CHRONIC LYMPHOCYTIC LEUKEMIA)
Phase 2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New CLL combo aims for Long-Term remission without lifelong pills
Disease control Not yet recruitingThis phase II trial tests a new drug called pirtobrutinib combined with a short course of chemotherapy in 82 fit patients with untreated CLL. The goal is to achieve deep remission with undetectable cancer cells in the blood at 24 months. The treatment lasts only 15 months, aiming…
Matched conditions: CLL (CHRONIC LYMPHOCYTIC LEUKEMIA)
Phase 2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for Hard-to-Treat blood cancers? early trial of MS-553 begins
Disease control Not yet recruitingThis early-phase trial is testing an experimental drug called MS-553 in 12 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to treatment. The main goal is to check the drug's safety and find the right dose…
Matched conditions: CLL (CHRONIC LYMPHOCYTIC LEUKEMIA)
Phase 1/2 • Sponsor: MingSight Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC